|
[1]
|
Iwakiri, Y. and Trebicka, J. (2021) Portal Hypertension in Cirrhosis: Pathophysiological Mechanisms and Therapy. JHEP Reports, 3, Article ID: 100316. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Gracia-Sancho, J., Marrone, G. and Fernández-Iglesias, A. (2019) Hepatic Microcirculation and Mechanisms of Portal Hypertension. Nature Reviews Gastroenterology & Hepatology, 16, 221-234. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ezhilarasan, D. (2020) Endothelin-1 in Portal Hypertension: The Intricate Role of Hepatic Stellate Cells. Experimental Biology and Medicine, 245, 1504-1512. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Su, W., Tai, Y., Tang, S.H., et al. (2020) Celecoxib Attenuates Hepatocyte Apoptosis by Inhibiting Endoplasmic Reticulum Stress in Thioacetamide-Induced Cirrhotic Rats. World Journal of Gastroenterology, 26, 4094-4107. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Xia, S.W., Wang, Z.M., Sun, S.M., et al. (2020) Endoplasmic Reticulum Stress and Protein Degradation in Chronic Liver Disease. Pharmacological Research, 161, Article ID: 105218. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Moctezuma-Velazquez, C., Kalainy, S. and Abraldes, J.G. (2017) Beta-Blockers in Patients with Advanced Liver Disease: Has the Dust Settled? Liver Transplantation, 23, 1058-1069. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Rodrigues, S.G., Mendoza, Y.P. and Bosch, J. (2020) Beta-Blockers in Cirrhosis: Evidence-Based Indications and Limitations. JHEP Reports, 2, Article ID: 100063. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Dwinata, M., Putera, D.D., Adda’I., M.F., et al. (2019) Carvedilol vs Endoscopic Variceal Ligation for Primary and Secondary Prevention of Variceal Bleeding: Systematic Review and Meta-Analysis. World Journal of Gastroenterology, 11, 464-476. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Malandris, K., Paschos, P., Katsoula, A., et al. (2019) Carvedilol for Prevention of Variceal Bleeding: A Systematic Review and Meta-Analysis. Annals of Gastroenterology, 32, 287-297. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Tsai, H.C., Hsu, C.F., Huang, C.C., et al. (2020) Propranolol Suppresses the T-Helper Cell Depletion-Related Immune Dysfunction in Cirrhotic Mice. Cells, 9, Article No. 604. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Sasso, R. and Rockey, D.C. (2021) Non-Selective Beta-Blocker Use in Cirrhotic Patients Is Associated with a Reduced Likelihood of Hospitalisation for Infection. Alimentary Pharmacology & Therapeutics, 53, 418-425.
|
|
[12]
|
Trebicka, J., Hennenberg, M., Laleman, W., et al. (2007) Atorvastatin Lowers Portal Pressure in Cirrhotic Rats by Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase. Hepatology, 46, 242-253. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Rosenson, R.S., Baker, S.K., Jacobson, T.A., et al. (2014) An Assessment by the Statin Muscle Safety Task Force: 2014 Update. Journal of Clinical Lipidology, 8, S58-S71. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Muñoz, A.E., Pollarsky, F.D., Marino, M., et al. (2021) Addition of Statins to the Standard Treatment in Patients with Cirrhosis: Safety and Efficacy. World Journal of Gastroenterology, 27, 4639-4652. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Asl, M.N. and Hosseinzadeh, H. (2008) Review of Pharmacological Effects of Glycyrrhiza sp. and Its Bioactive Compounds. Phytotherapy Research, 22, 709-724. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Pun, C.K., Huang, H.C., Chang, C.C., et al. (2021) Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats. International Journal of Molecular Sciences, 22, Article No. 7662. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Liang, B., Guo, X.L., Jin, J., et al. (2015) Glycyrrhizic Acid Inhibits Apoptosis and Fibrosis in Carbon-Tetrachloride-Induced Rat Liver Injury. World Journal of Gastroenterology, 21, 5271-5280. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Tu, C.T., Li, J., Wang, F.P., et al. (2012) Glycyrrhizin Regulates CD4+ T Cell Response during Liver Fibrogenesis via JNK, ERK and PI3K/AKT Pathway. International Immunopharmacology, 14, 410-421. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Kreisel, W., Schaffner, D., Lazaro, A., et al. (2020) Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. International Journal of Molecular Sciences, 21, Article No. 6223. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Leung, T.M., Tipoe, G.L., Liong, E.C., et al. (2008) Endothelial Nitric Oxide Synthase Is a Critical Factor in Experimental Liver Fibrosis. International Journal of Experimental Pathology, 89, 241-250. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Pietrosi, G., Fernández-Iglesias, A., Pampalone, M., et al. (2020) Human Amniotic Stem Cells Improve Hepatic Microvascular Dysfunction and Portal Hypertension in Cirrhotic Rats. Liver International, 40, 2500-2514. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Funk, C.D. (2001) Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology. Science, 294, 1871-1875. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Tai, Y., Zhao, C., Zhang, L., et al. (2021) Celecoxib Reduces Hepatic Vascular Resistance in Portal Hypertension by Amelioration of Endothelial Oxidative Stress. Journal of Cellular and Molecular Medicine, 25, 10389-10402. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Gao, J.H., Wen, S.L., Yang, W.J., et al. (2013) Celecoxib Ameliorates Portal Hypertension of the Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis. Plos ONE, 8, e69309. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Wen, S.L., Gao, J.H., Yang, W.J., et al. (2014) Celecoxib Attenuates Hepatic Cirrhosis through Inhibition of Epithelial-to-Mesenchymal Transition of Hepatocytes. Journal of Gastroenterology and Hepatology, 29, 1932-1942. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Hui, A.Y., Leung, W.K., Chan, H.L., et al. (2006) Effect of Celecoxib on Experimental Liver Fibrosis in Rat. Liver International, 26, 125-136. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Liu, H., Wei, W. and Li, X. (2009) Celecoxib Exacerbates Hepatic Fibrosis and Induces Hepatocellular Necrosis in Rats Treated with Porcine Serum. Prostaglandins & Other Lipid Mediators, 88, 63-67. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Yu, J., Hui, A.Y., Chu, E.S., et al. (2009) The Anti-Inflammatory Effect of Celecoxib Does Not Prevent Liver Fibrosis in Bile Duct-Ligated Rats. Liver International, 29, 25-36. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Deng, W., Zhu, Y., Lin, J., et al. (2017) Inhibition of Soluble Epoxide Hydrolase Lowers Portal Hypertension in Cirrhotic Rats by Ameliorating Endothelial Dysfunction and Liver Fibrosis. Prostaglandins & Other Lipid Mediators, 131, 67-74. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Harris, T.R., Bettaieb, A., Kodani, S., et al. (2015) Inhibition of Soluble Epoxide Hydrolase Attenuates Hepatic Fibrosis and Endoplasmic Reticulum Stress Induced by Carbon Tetrachloride in Mice. Toxicology and Applied Pharmacology, 286, 102-111. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Steib, C.J., Schewe, J. and Gerbes, A.L. (2015) Infection as a Trigger for Portal Hypertension. Digestive Diseases, 33, 570-576. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
De Mesquita, F.C., Guixé-Muntet, S., Fernández-Iglesias, A., et al. (2017) Liraglutide Improves Liver Microvascular Dysfunction in Cirrhosis: Evidence from Translational Studies. Scientific Reports, 7, Article No. 3255. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Ko, M.T., Huang, H.C., Lee, W.S., et al. (2017) Metformin Reduces Intrahepatic Fibrosis and Intrapulmonary Shunts in Biliary Cirrhotic Rats. Journal of the Chinese Medical Association, 80, 467-475. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Hwang, J.H., Shergill, A.K., Acosta, R.D., et al. (2014) The Role of Endoscopy in the Management of Variceal Hemorrhage. Gastrointestinal Endoscopy, 80, 221-227. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Kulkarni, A.V., Arab, J.P., Premkumar, M., et al. (2020) Terlipressin Has Stood the Test of Time: Clinical Overview in 2020 and Future Perspectives. Liver International, 40, 2888-2905. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Avgerinos, A., Sgouros, S., Viazis, N., et al. (2005) Somatostatin Inhibits Gastric Acid Secretion More Effectively than Pantoprazole in Patients with Peptic Ulcer Bleeding: A Prospective, Randomized, Placebo-Controlled Trial. Scandinavian Journal of Gastroenterology, 40, 515-522. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Stanley, A.J. and Laine, L. (2019) Management of Acute Upper Gastrointestinal Bleeding. British Medical Journal, 364, Article No. l536. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Yu, T., Tang, Y., Jiang, L., et al. (2016) Proton Pump Inhibitor Therapy and Its Association with Spontaneous Bacterial Peritonitis Incidence and Mortality: A Meta-Analysis. Digestive and Liver Disease, 48, 353-359. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Trikudanathan, G., Israel, J., Cappa, J., et al. (2011) Association between Proton Pump Inhibitors and Spontaneous Bacterial Peritonitis in Cirrhotic Patients—A Systematic Review and Meta-Analysis. International Journal of Clinical Practice, 65, 674-678. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
An, Y., Bai, Z., Xu, X., et al. (2020) No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis. BioMed Research International, 2020, Article ID: 4097170. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Fry, L.C., Neumann, H., Olano, C., et al. (2008) Efficacy, Complications and Clinical Outcomes of Endoscopic Sclerotherapy with N-Butyl-2-Cyanoacrylate for Bleeding Gastric Varices. Digestive Diseases, 26, 300-303. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Hu, T., Stock, S., Hong, W., et al. (2020) Modified ‘Sandwich’ Injection with or without Ligation for Variceal Bleeding in Patients with Both Esophageal and Gastric Varices: A Retrospective Cohort Study. Scandinavian Journal of Gastroenterology, 55, 1219-1224. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Smith, M.R., Tidswell, R. and Tripathi, D. (2014) Outcomes of Endoscopic Human Thrombin Injection in the Management of Gastric Varices. European Journal of Gastroenterology & Hepatology, 26, 846-852. [Google Scholar] [CrossRef]
|
|
[44]
|
Changela, K., Papafragkakis, H., Ofori, E., et al. (2015) Hemostatic Powder Spray: A New Method for Managing Gastrointestinal Bleeding. Therapeutic Advances in Gastroenterology, 8, 125-135. [Google Scholar] [CrossRef]
|
|
[45]
|
Dai, C., Liu, W.X., Jiang, M., et al. (2015) Endoscopic Variceal Ligation Compared with Endoscopic Injection Sclerotherapy for Treatment of Esophageal Variceal Hemorrhage: A Meta-Analysis. World Journal of Gastroenterology, 21, 2534-2541. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Sarin, S.K., Kumar, A., Angus, P.W., et al. (2011) Diagnosis and Management of Acute Variceal Bleeding: Asian Pacific Association for Study of the Liver Recommendations. Hepatology International, 5, 607-624. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Marot, A., Trépo, E., Doerig, C., et al. (2015) Systematic Review with Meta-Analysis: Self-Expanding Metal Stents in Patients with Cirrhosis and Severe or Refractory Oesophageal Variceal Bleeding. Alimentary Pharmacology & Therapeutics, 42, 1250-1260. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Escorsell, À., Pavel, O., Cárdenas, A., et al. (2016) Esophageal Balloon Tamponade versus Esophageal Stent in Controlling Acute Refractory Variceal Bleeding: A Multicenter Randomized, Controlled Trial. Hepatology, 63, 1957-1967. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Cejna, M., Peck-Radosavljevic, M., Thurnher, S.A., et al. (2001) Creation of Transjugular Intrahepatic Portosystemic Shunts with Stent-Grafts: Initial Experiences with a Polytetrafluoroethylene-Covered Nitinol Endoprosthesis. Radiology, 221, 437-446. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Li, S., Zhang, C., Lin, L.L., et al. (2020) Early-TIPS versus Current Standard Therapy for Acute Variceal Bleeding in Cirrhosis Patients: A Systemic Review with Meta-Analysis. Frontiers in Pharmacology, 11, Article No. 603. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Gaba, R.C., Bui, J.T., Cotler, S.J., et al. (2010) Rebleeding Rates Following TIPS for Variceal Hemorrhage in the Viatorr Era: TIPS Alone versus TIPS with Variceal Embolization. Hepatology International, 4, 749-756. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Kang, S.H., Lee, Y.B., Lee, J.H., et al. (2017) Rifaximin Treatment Is Associated with Reduced Risk of Cirrhotic Complications and Prolonged Overall Survival in Patients Experiencing Hepatic Encephalopathy. Alimentary Pharmacology & Therapeutics, 46, 845-855. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Butterworth, R.F. and Mcphail, M.J.W. (2019) L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. Drugs, 79, 31-37. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Butterworth, R.F. (2020) Beneficial Effects of L-Ornithine L-Aspartate for Prevention of Overt Hepatic Encephalopathy in Patients with Cirrhosis: A Systematic Review with Meta-Analysis. Metabolic Brain Disease, 35, 75-81. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Ampuero, J., Ranchal, I., Nuñez, D., et al. (2012) Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy. PLoS ONE, 7, e49279. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Numan, L., Elkafrawy, A., Kaddourah, O., et al. (2020) Spontaneous Bacterial Peritonitis: We Are Still Behind. Cureus, 12, e7711. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Rogers, G.B., Van Der Gast, C.J., Bruce, K.D., et al. (2013) Ascitic Microbiota Composition Is Correlated with Clinical Severity in Cirrhosis with Portal Hypertension. PLoS ONE, 8, e74884. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Dever, J.B. and Sheikh, M.Y. (2015) Review Article: Spontaneous Bacterial Peritonitis—Bacteriology, Diagnosis, Treatment, Risk Factors and Prevention. Alimentary Pharmacology & Therapeutics, 41, 1116-1131. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Pimentel, R., Gregório, C. and Figueiredo, P. (2021) Antibiotic Prophylaxis for Prevention of Spontaneous Bacterial Peritonitis in Liver Cirrhosis: Systematic Review. Acta Gastro-Enterologica Belgica, 84, 333-342.
|
|
[60]
|
Wang, W., Yang, J., Liu, C., et al. (2019) Norfloxacin, Ciprofloxacin, Trimethoprim-Sulfamethoxazole, and Rifaximin for the Prevention of Spontaneous Bacterial Peritonitis: A Network Meta-Analysis. European Journal of Gastroenterology & Hepatology, 31, 905-910. [Google Scholar] [CrossRef]
|